Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
5-fluorouracil · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| pegfilgrastim | DRUG | - |
| cyclophosphamide | DRUG | - |
| methotrexate | DRUG | - |
| 5-fluorouracil | DRUG | - |
Inclusion Criteria: - Histologically confirmed breast cancer Stage I, II or III - Candidate for IV CMF chemotherapy (every 4 weeks) for a total of 6 cycles - Chemotherapy naïve (prior treatment with hormone therapy or with anti-HER2 monoclonal antibody therapy is permitted as long as treatment has b...
Top 20 of 92 competitors
5-fluorouracil is a small molecule being studied for use in breast cancer. It is currently in Phase 2 clinical development as part of a combination regimen with cyclophosphamide and methotrexate, known as CMF, along with pegfilgrastim. The drug is being investigated for its potential role in treating patients with breast cancer.
5-fluorouracil is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker AMGN. Amgen is conducting clinical research on this drug for the treatment of breast cancer.
5-fluorouracil is in Phase 2 clinical development for breast cancer. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug remains under investigation for this indication.
5-fluorouracil is associated with clinical trial NCT00124111, titled "A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer." This Phase 2 trial has been completed and enrolled adult patients with breast cancer.
5-fluorouracil is a small molecule chemotherapeutic agent. It is used in combination with cyclophosphamide and methotrexate as part of the CMF regimen for breast cancer. The drug is being studied for its ability to treat this disease, though the specific molecular target has not been disclosed.
5-fluorouracil is one component of the CMF regimen, which also includes cyclophosphamide and methotrexate. The clinical trial NCT00124111 studies the combination of these three drugs along with pegfilgrastim in patients with breast cancer. 5-fluorouracil itself is not synonymous with the full CMF regimen.